Sezer O - Search Results

1

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.

Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A, Heider U, Fleissner C, Kaiser M, von Metzler I, Müller C, Sezer O. Jakob C, et al. Among authors: sezer o. Leukemia. 2008 Sep;22(9):1767-72. doi: 10.1038/leu.2008.159. Epub 2008 Jun 26. Leukemia. 2008. PMID: 18580957

2

Bortezomib inhibits human osteoclastogenesis.

von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O. von Metzler I, et al. Among authors: sezer o. Leukemia. 2007 Sep;21(9):2025-34. doi: 10.1038/sj.leu.2404806. Epub 2007 Jun 21. Leukemia. 2007. PMID: 17581612

3

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K. Sezer O, et al. Ann Hematol. 2000 Oct;79(10):574-7. doi: 10.1007/s002770000236. Ann Hematol. 2000. PMID: 11100749

4

Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.

Sezer O, Heider U, Zavrski I, Possinger K. Sezer O, et al. Haematologica. 2001 Aug;86(8):837-43. Haematologica. 2001. PMID: 11522540

5

Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma.

Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, Kaufmann O, Possinger K. Sezer O, et al. Ann Hematol. 2001 Oct;80(10):598-601. doi: 10.1007/s002770100361. Ann Hematol. 2001. PMID: 11732871

6

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer.

Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O. Langelotz C, et al. Among authors: sezer o. Br J Cancer. 2003 May 6;88(9):1406-10. doi: 10.1038/sj.bjc.6600935. Br J Cancer. 2003. PMID: 12778070 Free PMC article.

7

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.

Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, Rötzer S, Müller C, Kaiser M, Fleissner C, Heider U, Neumayer HH, Sezer O. Kleeberg L, et al. Among authors: sezer o. Eur J Med Res. 2009;14(2):47-54. doi: 10.1186/2047-783x-14-2-47. Eur J Med Res. 2009. PMID: 19258212 Free PMC article.

8

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.

Sezer O, Jakob C, Eucker J, Niemöller K, Gatz F, Wernecke K, Possinger K. Sezer O, et al. Eur J Haematol. 2001 Feb;66(2):83-8. doi: 10.1034/j.1600-0609.2001.00348.x. Eur J Haematol. 2001. PMID: 11168514

9

Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.

Sezer O, Niemöller K, Kaufmann O, Eucker J, Jakob C, Zavrski I, Possinger K. Sezer O, et al. Eur J Haematol. 2001 Apr;66(4):238-44. doi: 10.1034/j.1600-0609.2001.066004238.x. Eur J Haematol. 2001. PMID: 11380603

10

Proteasome as an emerging therapeutic target in cancer.

Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O. Zavrski I, et al. Among authors: sezer o. Curr Pharm Des. 2007;13(5):471-85. doi: 10.2174/138161207780162908. Curr Pharm Des. 2007. PMID: 17348844 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters